首页|期刊导航|中国实验方剂学杂志|沙参麦冬汤调控JAK2/STAT3信号通路对Lewis肺癌模型小鼠化疗增效机制

沙参麦冬汤调控JAK2/STAT3信号通路对Lewis肺癌模型小鼠化疗增效机制OA

Shashen Maidong Tang Enhances Efficacy of Chemotherapy in Mouse Model of Lewis Lung Cancer by Modulating JAK2/STAT3 Signaling Pathway

中文摘要英文摘要

目的:利用网络药理学预测沙参麦冬汤对肺癌化疗增效的作用机制,并进行动物实验验证.方法:通过网络药理学、液相色谱-质谱法(LC-MS)、分子对接方法预测沙参麦冬汤对肺癌化疗增效的潜在作用机制.将C57/BL6小鼠分为正常组、模型组、顺铂组、沙参麦冬汤+顺铂组.除正常组外,其余各组皮下注射1×107个/mL的Lewis肺癌细胞0.2 mL,建立Lewis肺癌模型,沙参麦冬汤每日灌胃剂量为3.58 g·kg-1,顺铂隔日腹腔注射剂量为2 mg·kg-1,给药14 d.监测小鼠肿瘤体积变化及抑瘤率,苏木素-伊红(HE)染色观察肿瘤组织病理变化,酶联免疫吸附测定法(ELISA)检测外周血中白细胞介素-6(IL-6)、γ干扰素(IFN-γ)的含量变化,实时荧光定量聚合酶链式反应(Real-time PCR)检测小鼠肿瘤组织中Janus激酶2(JAK2)、信号转导及转录激活蛋白1(STAT1)、信号转导及转录激活蛋白3(STAT3)mRNA含量变化,蛋白免疫印迹法(Western blot)检测肿瘤组织中JAK2、STAT3、B淋巴细胞瘤-2(Bcl-2)、胱天蛋白酶-3(Caspase-3)、Pim-1原癌(PIM1)蛋白的表达变化,免疫组化法检测小鼠肿瘤组织中Bcl-2及PIM1蛋白表达水平.结果:网络药理学预测显示沙参麦冬汤对肺癌化疗增效机制可能与氮代谢、高级糖基化终末产物-受体(AGE-RAGE)信号通路、癌症通路、JAK/STAT信号通路等有关.动物实验验证结果显示,与模型组比较,造模后第14、17、20天顺铂组、沙参麦冬汤+顺铂组肿瘤组织体积明显减小(P<0.05);与顺铂组比较,造模后第17、20天沙参麦冬汤+顺铂组小鼠肿瘤体积明显减小(P<0.05),各组小鼠肿瘤体积对比图也显示出相同结果.与顺铂组比较,沙参麦冬汤+顺铂组抑瘤率明显升高(P<0.05);HE染色结果显示模型组小鼠肿瘤组织核分裂现象明显,细胞排列致密规律,核大深染,无明显坏死区域;顺铂组出现部分坏死区域及空泡化现象;沙参麦冬汤+顺铂组小鼠肿瘤组织中出现广泛坏死区域,空泡化面积最大,肿瘤细胞排列疏松无序,较少核分裂现象;与模型组比较,顺铂组及沙参麦冬汤+顺铂组外周血中IFN-γ的含量显著上升(P<0.01),IL-6的含量显著下降(P<0.01);与顺铂组比较,沙参麦冬汤+顺铂组小鼠外周血中IFN-γ的含量显著升高(P<0.01),IL-6的含量显著下降(P<0.01);与模型组比较,JAK2、STAT3 mRNA在顺铂组和沙参麦冬汤+顺铂组中显著降低(P<0.01),而STAT1 mRNA显著上升(P<0.01);与顺铂组比较,JAK2、STAT3 mRNA在沙参麦冬汤+顺铂组显著下调(P<0.01),STAT1 mRNA显著上调(P<0.01);与模型组相比较,顺铂组及沙参麦冬汤+顺铂组中JAK2、Bcl-2、PIM1蛋白显著降低(P<0.01),STAT3蛋白表达明显降低(P<0.05),Caspase-3蛋白显著升高(P<0.01);与顺铂比较,沙参麦冬汤+顺铂组中JAK2、Bcl-2、PIM1蛋白显著降低(P<0.01),STAT3蛋白显著降低(P<0.05),Caspase-3蛋白显著上升(P<0.01);免疫组化中Bcl-2、PIM1蛋白表达结果与Western blot中一致.结论:沙参麦冬汤可能通过调控JAK2/STAT3信号通路对Lewis肺癌模型小鼠化疗起增效作用.

Objective:To predict the mechanism through which Shasheng Maidong Tang enhances the efficacy of chemotherapy for lung cancer via network pharmacology and validate the prediction results in animal experiments.Methods:The potential mechanism through which Shasheng Maidong Tang enhances the efficacy of chemotherapy for lung cancer was predicted by network pharmacology,liquid chromatography-mass spectrometry(LC-MS),and molecular docking methods.C57/BL6 mice were assigned into normal,model,cisplatin,and Shasheng Maidong Tang+cisplatin groups.In addition to the normal group,the remaining groups were injected subcutaneously with 0.2 mL of 1×107 cells·mL-1 Lewis lung cancer cells to establish the Lewis lung cancer model.The daily gavage dose of Shasheng Maidong Tang was 3.58 g·kg-1,and the concentration of cisplatin intraperitoneally injected on every other day was 2 mg·kg-1.Drugs were administered for 14 d.The changes in the tumor volume and the rate of tumor suppression were monitored,and the tumor histopathological changes were observed by hematoxylin-eosin(HE)staining.Enzyme-linked immunosorbent assay was employed to measure the interleukin(IL)-6 and interferon(IFN)-γ levels in peripheral blood.Real-time PCR was performed to quantify the mRNA levels of Janus kinase 2(JAK2),signal transducer and activator of transcription 1(STAT1),and signal transducer and activator of transcription 3(STAT3)in the tumor tissue of mice.Western blot was employed to determine the protein levels of JAK2,STAT3,B-cell lymphoma-2(Bcl-2),cysteinyl aspartate-specific proteinase-3(Caspase-3),and Pim-1 proto1(PIM1)in the tumor tissue.Immunohistochemistry was employed to detect the expression of Bcl-2 and PIM1 in the tumor tissue.Results:Network pharmacological predictions indicated that Shasheng Maidong Tang might enhance the efficacy of chemotherapy for lung cancer by regulating nitrogen metabolism,AGE-RAGE signaling pathway,cancer pathway,and JAK/STAT signaling pathway.The experimental results demonstrated that tumor volume in the cisplatin group and Shasheng Maidong Tang+cisplatin group was reduced compared with the model group,with statistically distinct differences observed on days 14,17,20 post modeling(P<0.05).Notably,the Shasheng Maidong Tang+cisplatin therapy further decreased tumor volume compared with the cisplatin group,showing marked reductions on days 17 and 20(P<0.05),consistent with trends visualized in tumor volume comparison charts.The Shasheng Maidong Tang+cisplatin group exhibited higher tumor inhibition rate than the cisplatin group(P<0.05).Histopathological analysis via HE staining revealed that the tumors in the model group displayed frequent nuclear mitosis,densely arranged cells,hyperchromatic nuclei,and no necrosis.Cisplatin treatment induced partial necrosis and vacuolization,while the Shasheng Maidong Tang+cisplatin group exhibited extensive necrotic regions,maximal vacuolization,disarranged tumor cells,and minimal mitotic activity.Compared with the model group,the cisplatin group and the Shasheng Maidong Tang+cisplatin group showed elevated level of IFN-γ(P<0.01)and declined level of IL-6(P<0.01)in the peripheral blood.Compared with the cisplatin group,the Shasheng Maidong Tang+cisplatin group presented elevated level of IFN-γ(P<0.01)and lowered level of IL-6(P<0.01)in the peripheral blood.Compared with the model group,the cisplatin group and the Shasheng Maidong Tang+cisplatin groups showed down-regulated mRNA levels of JAK2 and STAT3(P<0.01)and up-regulated mRNA level STAT1(P<0.01).Compared with the cisplatin group,the Shasheng Maidong Tang+cisplatin group presented down-regulated mRNA levels of JAK2 and STAT3(P<0.01)and up-regulated mRNA level of STAT1(P<0.01).Compared with the model group,the cisplatin group and the Shasheng Maidong Tang+cisplatin group showed down-regulated protein levels of JAK2(P<0.01),Bcl-2(P<0.01),PIM1(P<0.01),and STAT3(P<0.05),and up-regulated protein level of Caspase-3(P<0.01).Compared with the cisplatin group,Shasheng Maidong Tang+cisplatin group presented down-regulated protein levels of JAK2(P<0.01),Bcl-2(P<0.01),PIM1(P<0.01),STAT3(P<0.05),and up-regulated protein level of Caspase-3(P<0.01).The Bcl-2 and PIM1 expression results obtained by immunohistochemistry were consistent with those of Western blot.Conclusion:Shasheng Maidong Tang may enhance the efficacy of chemotherapy in the mouse model of Lewis lung cancer by regulating the JAK2/STAT3 signaling pathway.

余霖;王瑶瑶;刘丽敏;胡作为;周燕萍;王上

湖北中医药大学中医学院,武汉 430061||湖北时珍实验室,武汉 430065湖北中医药大学中医学院,武汉 430061||湖北时珍实验室,武汉 430065湖北中医药大学中医学院,武汉 430061||湖北时珍实验室,武汉 430065湖北省武汉市第一医院,武汉 430030湖北中医药大学中医学院,武汉 430061||湖北时珍实验室,武汉 430065湖北中医药大学中医学院,武汉 430061||湖北时珍实验室,武汉 430065

医药卫生

沙参麦冬汤Lewis肺癌网络药理学Janus激酶2/信号转导及转录激活蛋白3(JAK2/STAT3)信号通路化疗

Shasheng Maidong TangLewis lung cancernetwork pharmacologyJanus kinase 2/signal transducer and activator of transcription 3(JAK2/STAT3)signaling pathwaychemotherapy

《中国实验方剂学杂志》 2026 (5)

1-10,10

湖北省自然科学基金联合基金项目(2023AFD137)湖北省中医药科研项目(ZY2021M023)

10.13422/j.cnki.syfjx.20251023

评论